MedTrace Logo

Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors

NCT03552406 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2021-05-06

No results posted yet for this study

Summary

A phase I, open-label, dose-finding study to assess the safety, tolerability and pharmacokinetics of ISU104, a human monoclonal antibody targeting erbB3 in patients with advanced solid tumors.

Conditions

Interventions

BIOLOGICAL

ISU104

Intravenous Infusion for 1 hour.

DRUG

Cetuximab

Intravenous Infusion for 1 hour (2 hours at initial dose)

Sponsors & Collaborators

  • ISU Abxis Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jaehyeon Juhn, Ph.D · ISU Abxis Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-27
Primary Completion
2020-10-19
Completion
2021-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03552406 on ClinicalTrials.gov